Tari A. King, MD, FSSO, on the Past Year in Breast Cancer Research

Video

The breast cancer expert discussed the latest developments in breast cancer research and what she hopes the next year will offer this patient population.

With breast cancer being the most common cancer among women in the US outside of skin cancers, it is as important as ever for research to continue to advance treatments for this patient population.

According to the American Cancer Society, an estimated 276,480 new cases of invasive breast cancer were diagnosed in women in 2020 and an estimated 48,530 new cases of carcinoma in situ were diagnosed. Moreover, the organization estimated that approximately 42,170 women would die from breast cancer.

In an interview with CancerNetwork®, Tari A. King, MD, FSSO, associate chair for Multidisciplinary Oncology in the Department of Surgery and chief of the Division of Breast Surgery at Dana-Farber Cancer Institute/Brigham and Women’s Cancer Center, as well as Anne E. Dyson Professor of Surgery in the Field of Women’s Cancers at Harvard Medical School, spoke about the latest developments in breast cancer research and what she hopes 2021 will bring for this patient population.

This segment comes from the CancerNetwork® portion of the MJH Life Sciences Medical World News, airing daily on all MJH Life Sciences channels.

Reference:

American Cancer Society. How Common Is Breast Cancer? American Cancer Society website. Published January 8, 2020. Accessed December 21, 2020. https://www.cancer.org/cancer/breast-cancer/about/how-common-is-breast-cancer.html

Recent Videos
Breast cancer care providers make it a goal to manage the adverse effects that patients with breast cancer experience to minimize the burden of treatment.
Social workers and case managers may have access to institutional- or hospital-level grants that can reduce financial toxicity for patients undergoing cancer therapy.
Insurance and distance to a tertiary cancer center were 2 barriers to receiving high-quality breast cancer care, according to Rachel Greenup, MD, MPH.
Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer. Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer.
ADCs demonstrate superior efficacy vs chemotherapy but maintain a similar efficacy profile that requires multidisciplinary collaboration to optimally treat.
According to Aditya Bardia, MD, MPH, FASCO, antibody-drug conjugates are slowly replacing chemotherapy as a standard treatment for breast cancer.
Administering oral SERD-based regimens may enhance patients’ quality of life when undergoing treatment for ER-positive, HER2-negative breast cancer.
Gedatolisib-based triplet regimens may be effective among patients with prior endocrine resistance or rapid progression following frontline therapy.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content